HAGP1MAG-12K

MILLIPLEX^® Human Angiogenesis Panel

Name: MILLIPLEX<SUP>®</SUP> Human Angiogenesis Panel
Brand: MM

Configurable Human Angiogenesis/Growth Factor 17-Plex Panel 1

Synonym(s):

human oncology growth factor immunoassay panel, luminex human cancer angiogenesis growth factor multiplex assay, millipore human cancer growth factor protein multiplex kit

About This Item

UNSPSC Code:

12161503

NACRES:

NA.84

eCl@ss:

32161000

Key Documents

View All Documentation

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

MILLIPLEX^® Human Angiogenesis Panel, Configurable Human Angiogenesis/Growth Factor 17-Plex Panel 1

species reactivity

human

manufacturer/tradename

Milliplex^®

Quality Level

200

packaging

1 ea of

assay range

accuracy: 42-131%
standard curve range: 1.4-1,000 pg/mL
(HB-EGF, IL-8, PLGF)
standard curve range: 13.7-10,000 pg/mL
(Angiopoietin-2, FGF-1, FGF-2, G-CSF, VEGF-A)
standard curve range: 137.2-100,000 pg/mL
(Leptin)
standard curve range: 2.7-2,000 pg/mL
(BMP-9, EGF, Endothelin-1)
standard curve range: 27.4-20,000 pg/mL
(Endoglin, Follistatin, HGF)
standard curve range: 6.9-5,000 pg/mL
(VEGF-C, VEGF-D)

technique(s)

multiplexing: suitable

input

serum plasma (Cell culture, cell culture supernatants)

detection method

fluorometric (Luminex^® xMAP^® technology)

shipped in

wet ice

storage temp.

2-8°C

Related Categories

Immunoassay Platform Solutions

MILLIPLEX^® Multiplex Assays for Luminex^® Instruments

Biochem/physiol Actions

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Preparation Note

Recommended storage for kit components is 2 - 8°C.

Legal Information

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Features and Benefits

Comprehensive 17-Biomarker Analysis: This innovative panel enables the simultaneous quantification of 17 critical angiogenesis and growth factor biomarkers, including Angiopoietin-2, BMP-9, EGF, VEGF-A, and more, providing a holistic view of the angiogenic process.
Versatile Sample Compatibility: Designed for use with human plasma, serum, tissue/cell lysates, and culture supernatants, offering flexibility for a variety of research applications.
Efficient 96-Well Format: Capable of measuring up to 38 samples in duplicate, this format enhances throughput while conserving valuable sample volume, making it ideal for high-volume studies.
Luminex^® xMAP^® Technology: Utilizes a magnetic bead immunoassay format for fast and sensitive quantification of multiple analytes, ensuring high accuracy and efficiency in your research.
In-Depth Insights into Angiogenesis: By quantifying multiple biomarkers simultaneously, researchers can gain a deeper understanding of the mechanisms regulating blood vessel formation, which is crucial for studying diseases such as cancer, cardiovascular disorders, and diabetic complications.

General description

Angiogenesis, the development of new vascular networks, is a key process in normal growth and development as well as in wound healing, with homeostasis maintained by a delicate balance of angiogenic factors and inhibitors. Consequently, insufficient, or excessive blood vessel growth underlies many diseases, including cardiovascular disease, diabetic ulcers, macular degeneration, and cancer. Angiogenesis plays a significant role in tumor growth and metastasis.

Application

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 17 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: Angiopoietin-2, BMP-9, EGF, Endoglin, Endothelin-1, FGF-1 (acidic FGF), FGF-2 (basic FGF), Follistatin, G-CSF, HB-EGF, HGF, IL-8, Leptin, PLGF, VEGF-A, VEGF-C and VEGF-D

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

pictograms

GHS08,GHS05,GHS07,GHS09

signalword

Danger

hcodes

H302 + H312 + H332,H317,H318,H373,H411

pcodes

P273 - P280 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P314

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Storage Class

10 - Combustible liquids

wgk

WGK 3

Regulatory Information

新产品

This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients.

Kevin P Daly et al.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 32(1), 120-128 (2012-12-25)

Cardiac allograft vasculopathy (CAV), the major cause of late allograft loss after cardiac transplantation, results from donor-directed cellular and humoral alloimmune responses. Graft vascular endothelial cells (EC) are primary targets of these destructive responses, suggesting that factors associated with endothelial

Cord Blood Biomarkers of Placental Maternal Vascular Underperfusion Predict Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension.

Karen K Mestan et al.

The Journal of pediatrics, 185, 33-41 (2017-02-07)

To assess whether cord blood biomarkers associated with placental maternal vascular underperfusion (MVU) are predictive of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH). Premature infants enrolled in a longitudinal cohort study were randomly sampled from 4 gestational age strata (n?=?190, range 23-36

Quantitative analysis of hormones and inflammatory cytokines in Chlamydia trachomatis-infected women with tubal ectopic pregnancy and early intrauterine pregnancy.

Ruijin Shao et al.

Data in brief, 6, 135-142 (2016-02-10)

In this data, non-pregnant women during the menstrual cycle, women with normal intrauterine pregnancy (IUP), and women with tubal ectopic pregnancy (EP) after informed consent were included. The serum levels of 17β-estradiol, progesterone, testosterone, beta-human chorionic gonadotropin, interleukin (IL)-1β, IL-4

Plasma vascular endothelial growth factor A and placental growth factor: novel biomarkers of pulmonary hypertension in congenital diaphragmatic hernia.

Neil Patel et al.

American journal of physiology. Lung cellular and molecular physiology, 308(4), L378-L383 (2014-12-07)

Pulmonary hypertension (PH) due to abnormal pulmonary vascular development is an important determinant of illness severity in congenital diaphragmatic hernia (CDH). Vascular endothelial growth factor A (VEGFA) and placental growth factor (PLGF) may be important mediators of pulmonary vascular development

Regulating VEGF signaling in platelet concentrates via specific VEGF sequestering.

David G Belair et al.

Biomaterials science, 4(5), 819-825 (2016-03-25)

Platelets contain an abundance of growth factors that mimic the composition of the wound healing milieu, and platelet-derived VEGF in particular can negatively influence wound healing if unregulated. Here, we sought to capture and regulate the activity of VEGF factor

View All Related Papers

MILLIPLEX® Human Angiogenesis Panel